Screen Shot 2020-02-16 at 11.55.32 AM
Screen Shot 2017-07-22 at 4.20.35 PM
Screen Shot 2020-02-16 at 11.52.38 AM
Screen Shot 2020-02-16 at 11.58.12 AM
Screen Shot 2020-02-16 at 11.57.48 AM
Screen Shot 2020-02-16 at 11.50.32 AM
Screen Shot 2017-07-22 at 3.14.09 PM_edited_edited
Screen Shot 2017-07-22 at 3.15.37 PM
Screen Shot 2017-07-22 at 4.15.36 PM
Screen Shot 2017-07-22 at 3.11.06 PM
Screen Shot 2017-07-22 at 4.17.09 PM
Screen Shot 2017-07-22 at 2.58.10 PM_edited
Screen Shot 2017-07-22 at 2.40.24 PM
Screen Shot 2017-07-22 at 2.41.51 PM
Screen Shot 2017-07-22 at 2.45.21 PM
Screen Shot 2017-07-22 at 2.44.25 PM
Screen Shot 2017-07-22 at 4.18.01 PM
Screen Shot 2017-07-22 at 2.28.11 PM
Screen Shot 2020-02-16 at 11.52.54 AM
Screen Shot 2017-07-22 at 3.19.22 PM
Screen Shot 2020-02-16 at 11.55.23 AM
Screen Shot 2017-07-22 at 4.17.01 PM
Screen Shot 2017-07-22 at 4.15.22 PM
Screen Shot 2017-07-22 at 4.14.51 PM
23and Me non
0x Aggregates DEX Liquidity and Pricing with New API
Author: Mitchell Moos CryptoBreifing.com
January 29th, 2020
Ethereum ERC-20 exchange protocol 0x is aggregating liquidity from Kyber, Uniswap, Oasis, and other decentralized exchanges to improve asset pricing and reduce slippage.
0x introduced a new set of open-source tools that aggregates on and off-chain DEX liquidity. By combining order books from the most popular decentralized exchanges, the tool helps mitigate issues of low-volume,
which is especially problematic among decentralized exchanges.
The low volume is evident when comparing between decentralized and centralized exchanges. The three DEXes facilitating the most trading volume — Kyber, Uniswap, and Oasis — posted just $6.7 million in 24-hour trading volume, according to DEXWatch. For comparison, Binance posted over $1.7 billion in volume over the same period.
Velano taps $25M in new funding for its needle-free, bedside blood draw system
Author:Conor Hale FierceBiotech.com
December 19th, 2019
Velano Vascular, maker of a needle-free blood draw system, has closed a second tranche of new financing with $25 million to put toward its commercialization and launch of additional access products and medical devices for the inpatient setting.
The funding follows up on an initial tranche of $10 million, secured by the company this past May. That included backing from Intermountain Healthcare—which previously rolled out the former Fierce 15 winner’s blood collection technology across all 22 of its Utah-area hospitals—as well as from other investors, entrepreneurs and philanthropists.
Author: Eric Ries LTSE.com
August 29th, 2019
The latest investment affirms the potential for a new generation of companies and long-term investors.
We started LTSE with a wild idea: to realign public capital markets around the needs of a generation of company builders and investors who measure success in years and decades, not financial quarters.
Since then, the idea has come to seem a little less out there. We hear over and over again from companies and investors that short-term pressures get in the way of long-term decision-making.
We recently closed a Series B round that added $50 million to LTSE's funding. Founders Fund, our lead for the Series A round, led the Series B with participation from insiders Collaborative Fund, Andreessen Horowitz, Obvious Ventures, Uprising, and Initialized.
LTSE raises an additional $50 million in funding
23andMe Just Got FDA Approval for a DNA Cancer Test
Author: Kristen V. Brown Bloomberg.com
January 22, 2019
DNA testing company 23andMe Inc. said it has gotten the green light from the U.S. Food and Drug Administration to offer consumers a test for a hereditary colorectal cancer syndrome.
23andMe said it will now be able to tell customers whether they have two genetic variants that influence MUTYH-associated polyposis, a rare
condition associated with an increased risk of colorectal cancer. The FDA didn’t immediately respond to a request for comment.
Connecting flight passengers and airlines to avoid denied boarding
Author: Toni Sekinah DataIQ.co.uk
July 15th, 2019
Fenn Bailey, who has a background in software engineering stretching back to the days of the dot com boom, is the co-founder and chief technology officer of travel technology company Volantio.
Fittingly for a company that assists airlines, it is global having been founded in Melbourne Australia in 2014 but now based in Atlanta, Georgia in the US.
Volantio’s main proposition is its Yana platform which launched in 2017 to help airlines to accommodate overbooked passengers.
Bailey said: “It is a very dynamic industry. Pricing changes, availability changes and aircraft move around. Often flights would fill up far quicker than the airline had estimated and they had no way to reach out to customers in a way that was connected to their system and see if they were willing to move to another flight.”
Nvidia Invests In Deepgram
For The Future Of Voice Recognition
Author: Savannah Dowling Crunchbase.com
March 30th, 2018
Deepgram previously raised seed funding from Boost VC in November 2015. The startup participated in Y Combinator’s winter 2016 batch after receiving a $120,000 investment from the accelerator. Later in September 2017, Deepgram raised $1.8 million in new financing led by Y Combinator and Compound with Zillionize Angel, Fenox Venture Capital, 1517 Fund, and Ludlow Ventures also participating in the round.